Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDPBOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Folia Health today announced a collaboration with argenx to launch a first-of-its-kind, at-home observational real-world evidence initiative supporting individuals living with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Folia Health Secures $10.5M in Funding to Transform Healthcare and Research With Patient-Reported InformationSeries A investment will advance the company’s efforts to give patients the power to drive research on rare diseases and chronic conditions
Folia Health and Inspire are Partnering to Bring Personalized Home Health Observations to the Forefront of Patient Focused Drug Development ResearchBOSTON, April 30, 2025 (GLOBE NEWSWIRE) -- Folia Health, the pioneer of patient-driven Home Reported Outcomes (HRO), has partnered with Inspire, the world's leading online health community and real-world data platform, to uniquely empower patients and caregivers with the opportunity to contribute a highly personalized form of structured at-home health observations data to accelerate patient-focused drug development research. In this collaboration, Folia and Inspire will focus on building longitudinal Real-World Evidence (RWE) Communities in some of the most complex and heterogeneous conditions to unlock insights that have been previously unattainable and unmeasurable in other data sources.
Folia Health Expands Its Rare Renal Disease Research with a New C3G Study to Assess Real-World Disease ImpactBOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Folia Health launches enrollment for an innovative, at-home real-world evidence initiative for individuals with C3 glomerulopathy (C3G). Designed in partnership with C3G clinicians and patients, this study uses Folia’s app-based platform to track home-reported outcomes (HROs) based on symptoms most relevant to participants—whether common to C3G or not, alongside their personalized treatment plan and monthly patient-reported outcomes (PROs) over an initial six-month observational period. This initiative, conducted in collaboration with Novartis Pharmaceuticals Corporation, aims to directly measure patient-defined burden and evaluate the impact of various treatments on quality of life.
Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA NephropathyBOSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA nephropathy. This ground-breaking study will leverage Folia’s cutting-edge technology platform, allowing participants to track changes and quality of life impacts based on the symptoms most relevant to them- whether commonly associated with IgAN or not- alongside their individual treatment plan during an initial six-month observational period. By enabling participants to self-select and define what’s most relevant to them, rather than relying solely on pre-specified patient-reported outcomes (PROs), this approach provides a comprehensive and nuanced understanding of the lived experiences of IgAN.
Folia Health Announces Groundbreaking Flare Tracking Technology to Bridge Research Gaps and Enhance Chronic Condition ManagementBOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Folia Health, a leader in patient-centric healthcare data analytics, is excited to announce the launch of its revolutionary proprietary, patent-pending Flare Tracking Technology, designed to transform the research and management of chronic conditions. This cutting-edge solution not only provides enhanced tools for patients and healthcare providers to monitor and manage disease flares with greater precision, but also fills critical research gaps, shedding light on what transpires between clinic visits, an irreparable blind spot in traditional types of healthcare data.
Folia Health Announces Distinguished Founding Members for its Scientific Advisory CouncilBOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Folia Health, the home-reported outcomes company, is proud to announce esteemed members of its Scientific Advisory Council. Composed of experts from diverse fields, the council will play a crucial role in Folia Health's commitment to advancing patient outcomes through evidence-based and patient-driven research.
Folia Health Reinforces Commitment to Autoimmune and Neurological Conditions: Announcing the Expansion of Multiple Sclerosis, Huntington's Disease, and Myasthenia Gravis User CohortsBOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Folia Health, a patient-focused health technology company, proudly announces a user cohort expansion of 3 conditions of great unmet need: Multiple Sclerosis (MS), Huntington's Disease (HD), and Myasthenia Gravis (MG). Leveraging its expertise in comprehensive patient experience data collection and analysis, through Home-Reported Outcomes (HROs), Folia Health aims to revolutionize the way research and care are approached in these complex conditions.
Folia Health joins the Cancer Moonshot’s CancerX Public-Private Partnership as a Founding MemberBOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Folia Health, a health technology company and a leader in patient-centered outcomes research, has announced today its participation in CancerX's inaugural research project “Advancing Digital Innovation to Improve Equity and Reduce Financial Toxicity in Cancer Care and Research.”
Folia Health launches user-led research program, the Canopy SeriesBOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Today, Folia Health announced a first-of-its-kind observational research initiative driven by the priorities of patient and caregiver users. This program, called the Canopy Series, will kick off with its inaugural report in June 2023, and is a brand-new type of research on the Folia home-reported outcomes (HRO) platform.
